Presumably the enterolignans are re-conjugated to
glucuronides and sulfates in the intestinal wall and in the liver.
Enterolignans have a similar structure to the human hormone
oestrogen and so may have estrogenic/anti-estrogenic effects.
Several epidemiological studies have shown a potential protective
effect of the enterolignans against hormone-dependent cancers,
especially breast cancer, and against cardiovascular diseases